Data investigation

How to Get a GLP-1 Prescription in 2026: The Patient Buyer Funnel

You can get semaglutide or tirzepatide through insurance (with prior authorization), brand direct-pay (Wegovy $199-$399, Zepbound $299-$449), compounded telehealth ($150-$400/month) or the $25 oral Foundayo path. Plus red flags.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·8 citations

This buyer's guide is part of Weight Loss Rankings' living editorial database — 1,160+ research articles and 630+ editorially reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

Most patients searching “how to get semaglutide” don't realize there are at least four legitimate paths to a GLP-1 prescription in the US in 2026 — each with different costs, different paperwork, and different waiting times. This is the buyer funnel: insurance, brand-name direct-pay, compounded telehealth, and the new oral Foundayo route. Plus the red flags that mean you're looking at an illegitimate seller, not a real pharmacy.

Compare vetted GLP-1 telehealth providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Starting price: $149/mo (+ required membership)

Get started →Read review Ro →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →

Step 1: Are you eligible at all?

The FDA-approved indication for chronic weight management with Wegovy[1] and Zepbound[2] is identical: adults with obesity, or adults with overweight plus at least one weight-related condition. The label itself doesn't give BMI numbers; in practice prescribers and insurers use the cutoffs the pivotal trials enrolled (BMI 30 is also the CDC's obesity line):

  • Adults with BMI ≥ 30 (any class of obesity), OR
  • Adults with BMI ≥ 27 AND at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or established cardiovascular disease.

If you're below BMI 27, you fall outside the trial-based eligibility prescribers use, and most insurance and brand-name direct-pay programs will not cover you either. You can check your eligibility in two minutes with our BMI calculator. Off-label prescribing exists but is rare for weight management at lower BMIs.

Two 2024 indication expansions you may also qualify under

Beyond the BMI-based weight-management indication, two FDA-approved indications added in 2024 may give you a different qualifying path:

  • Wegovy cardiovascular indication (March 8, 2024). Wegovy is FDA-approved to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight (no type 2 diabetes diagnosis required). The basis is the SELECT trial — see our SELECT trial deep-dive. This indication often unlocks insurance coverage that the weight-management indication alone does not.
  • Zepbound obstructive sleep apnea indication (December 20, 2024). Zepbound is FDA-approved for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, on the basis of the SURMOUNT-OSA trial (Malhotra et al. NEJM 2024, PMID 38912654). If you have a sleep study documenting moderate-to-severe OSA and BMI ≥30, this is a separate qualifying indication that some insurers cover even when they exclude weight-management indications.

Labs your prescriber will typically order

Most PCPs and telehealth platforms run a baseline lab panel before initiating a GLP-1. Typical pre-prescription labs:

  • HbA1c — to screen for undiagnosed type 2 diabetes and document a baseline if you have prediabetes
  • Comprehensive metabolic panel (CMP) — renal function (creatinine, eGFR) and liver enzymes (AST, ALT) baseline
  • Lipid panel — total cholesterol, LDL, HDL, triglycerides — to document the cardiometabolic starting point and qualify for the BMI ≥27 + dyslipidemia comorbidity pathway if relevant
  • TSH (thyroid stimulating hormone) — many prescribers screen for hypothyroidism, which can both mimic weight-resistance and is relevant given the GLP-1 class boxed warning for thyroid C-cell tumors
  • Personal and family history review for medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, gallbladder disease, and pregnancy plans

Path 1 — Through insurance

The cheapest path if it works, and the most paperwork-heavy.

1a. Check if your plan covers GLP-1s for weight management

Most commercial insurance plans cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro). Far fewer cover them for weight management (Wegovy, Zepbound). Coverage varies by employer, not just by carrier — Aetna at one employer might cover Wegovy with prior authorization while Aetna at a different employer carves it out completely. The fastest way to find out is:

  • Use our insurance employer checker to see what 30 large US employers cover.
  • Call the member-services number on the back of your insurance card and ask specifically: “Is Wegovy on my formulary for weight management? What about Zepbound? Is prior authorization required? What is my copay at each tier?”
  • Check our insurance coverage 2026 article for the Medicare, Medicaid, and commercial landscape.

1b. Get a prescriber to write the prescription

You need either a PCP, an obesity-medicine physician, or an endocrinologist who is willing to prescribe a GLP-1 for weight management. Bring documented BMI from a clinical visit (not self-reported) and any comorbidity diagnoses (lab values for diabetes or pre-diabetes, blood pressure readings for hypertension, sleep study results for OSA).

1c. Survive prior authorization

Almost all insurance approvals for weight-management GLP-1s require a prior authorization (PA) form. The PA typically asks for:

  • Documented BMI ≥ 30 (or ≥ 27 with a specific comorbidity)
  • Documentation of a previous lifestyle program (diet, exercise, often a specific commercial program like Weight Watchers, Noom, or a hospital-based program)
  • Often a previous medication trial (Qsymia, Contrave, phentermine — “step therapy”)
  • Sometimes a sleep study or other comorbidity workup

The PA process typically takes 3-14 days. Denials are common; most can be appealed successfully if your prescriber provides additional clinical documentation.

Realistic out-of-pocket on insurance: if your plan covers the drug at the brand tier, copays range from $25-$100/month for most commercial plans. If you have a high-deductible plan, you may pay full retail until you meet the deductible.

Path 2 — Brand-name direct-pay (no insurance, no PA)

Both Novo Nordisk and Eli Lilly run patient-direct cash-pay programs that bypass insurance and PBM step therapy entirely. This is the path most patients take when their insurance doesn't cover weight-management GLP-1s.

2a. Wegovy NovoCare[3]

  • $349/month for the standard pen (0.25 mg to 2.4 mg), and $399/month for the Wegovy HD 7.2 mg pen. Available to anyone in the US with a valid prescription, no insurance required.
  • $199/month for a new patient's first two months of 0.25 mg and 0.5 mg if you're paying out of pocket and not using insurance. Includes free shipping.
  • You still need a prescription from a US-licensed prescriber. NovoCare does not include the prescriber visit.

2b. Zepbound LillyDirect[4]

Lilly cut LillyDirect Zepbound prices on December 1, 2025. Current self-pay tiers:

  • $299/month for the 2.5 mg starter dose
  • $399/month for the 5 mg dose
  • $449/month for the 7.5 mg and higher doses if you refill within 45 days (otherwise $499 for 7.5 mg and $699 for 10-15 mg)
  • Available to any US patient with a valid prescription. LillyDirect ships to all 50 states.

2c. Foundayo (oral) — the new option[5]

Foundayo (orforglipron) is the first non-peptide oral GLP-1, FDA-approved April 1, 2026. Lilly is positioning it aggressively against the injectables on price:

  • $25/month with the Lilly Savings Card for commercially insured patients (not Medicare or Medicaid)
  • From $149/month self-pay for the 0.8 mg starting dose through LillyDirect; higher doses cost more, and the list price is $649/month
  • Pill, taken daily — no injection, no refrigeration
  • The highest FDA-approved dose (17.2 mg) produced 11.1% mean weight loss (vs 2.1% with placebo) in adults without type 2 diabetes at 72 weeks per the Foundayo prescribing information (less than Wegovy and Zepbound, but real)

Foundayo is the cheapest legal path to a brand-name GLP-1 in 2026 if you have commercial insurance. See our Foundayo approval deep-dive for the full clinical context.

Path 3 — Compounded telehealth

Compounded semaglutide and tirzepatide are made by 503A compounding pharmacies, not by Novo Nordisk or Lilly. They are typically prescribed and dispensed through telehealth platforms that bundle the prescriber visit, the medication, and the shipping into a single subscription. We rank these head to head in our best semaglutide providers guide.

3a. Pricing range

  • $150-$250/month for compounded semaglutide at most reputable telehealth platforms (Hims, Henry Meds, Mochi Health, EmpowerRX, etc.)
  • $250-$400/month for compounded tirzepatide
  • See our live compounded pricing index for the median, p10, and p90 across the entire telehealth market.

3b. The shortage status caveat

Compounded GLP-1s exist legally because of FDA drug shortage rules under section 503A of the Federal Food, Drug, and Cosmetic Act. Tirzepatide came off the FDA shortage list in October 2024[7], and semaglutide came off in early 2025. Compounding remains legal under the “clinical difference” provision (different dose, different concentration, different delivery), but FDA has issued multiple warning letters to compounders and marketers — see our FDA warning letters tracker.

3c. How to vet a compounded telehealth provider

  • PCAB accreditation on the dispensing pharmacy[8] — this is the gold standard for compounding quality.
  • Pharmacy state license — every legitimate compounder is registered with at least one US state board of pharmacy. The license number should be visible on the provider's site or available on request.
  • Real prescriber visit — a video visit or a structured intake reviewed by a physician, NP, or PA licensed in your state. If the provider just asks you to tick boxes on a form and ships the drug, that's a red flag.
  • See our PCAB accreditation investigation for our full vetting framework.

Path 4 — “Research peptides” and gray-market sellers (DON'T)

There is a large gray market of websites selling “research peptide” semaglutide and tirzepatide — vials labeled “not for human consumption” that are obviously marketed to humans. These are not legal pharmacies, are not regulated by the FDA, and have been the source of multiple contamination, dose-error, and counterfeit incidents.

The FDA has issued specific consumer warnings about unapproved GLP-1 products[6]. Red flags:

  • No prescription required, no prescriber visit
  • No state pharmacy license listed
  • Vials labeled “for research use only” or “not for human consumption”
  • Prices significantly below the legitimate compounded range (e.g., <$50/month for tirzepatide)
  • Payment in cryptocurrency only
  • Shipping from outside the US
  • No US business address or customer service phone number

The risks include incorrect dosing, contamination, counterfeit material with no active drug, and the lack of any recourse if something goes wrong. Don't do it.

Decision tree — which path probably fits you

  • You have commercial insurance and your plan covers weight-management GLP-1s → Path 1 (insurance). $25-$100/mo copay if approved.
  • You have commercial insurance but your plan does NOT cover weight management → Path 2c (Foundayo $25/mo with savings card) is the cheapest. Path 2a/2b ($199-$499/mo) if you specifically want an injectable.
  • You have no insurance at all → Path 3 (compounded, $150-$400/mo) is usually the cheapest — compare the cheapest semaglutide providers. Path 2 (NovoCare $349/mo after $199 for a new patient's first two months, or LillyDirect from $299) is more expensive but is brand-name and avoids any compounding uncertainty.
  • You have Medicare → coverage for weight management is limited; see our insurance coverage article for the current Medicare situation.
  • You have Medicaid → coverage varies enormously by state; some states cover with PA, many do not.

Magnitude comparison — monthly cost by access path

Magnitude comparison

Approximate out-of-pocket monthly cost across the four legitimate 2026 access paths. Insurance copay assumes plan covers weight management. Brand direct-pay tiers reflect current NovoCare and LillyDirect pricing; Foundayo reflects the Lilly Savings Card for commercially-insured patients.[3][4][5]

  • Foundayo (oral) — Lilly Savings Card, commercial insurance25 $/mo
    cheapest legal brand-name path if commercially insured
  • Insurance copay — plan covers weight management75 $/mo (midpoint $25–$100)
    Path 1; PA approval typically takes 3–14 days
  • Foundayo (oral) — cash-pay, 0.8 mg starting dose149 $/mo (higher doses cost more)
  • Compounded semaglutide (telehealth)200 $/mo (range $150–$250)
  • Wegovy NovoCare — new patient's first two months199 $/mo
  • LillyDirect Zepbound — 5 mg dose399 $/mo
  • Compounded tirzepatide (telehealth)325 $/mo (range $250–$400)
  • LillyDirect Zepbound — 7.5 mg+ dose449 $/mo
  • Wegovy NovoCare — standard pen349 $/mo
Approximate out-of-pocket monthly cost across the four legitimate 2026 access paths. Insurance copay assumes plan covers weight management. Brand direct-pay tiers reflect current NovoCare and LillyDirect pricing; Foundayo reflects the Lilly Savings Card for commercially-insured patients.

What this article is NOT

This is a buyer's guide, not a recommendation to buy. Whether a GLP-1 is right for you depends on your medical history, your weight loss goals, your budget, and your tolerance for the GI side effects covered in our side effect Q&A and nausea management guide. Discuss the decision with a prescribing clinician who knows your medical history before you start.

Bottom line

  • Four legitimate paths in 2026: insurance, brand-name direct-pay (NovoCare/LillyDirect/Foundayo savings card), compounded telehealth, and Medicaid/Medicare.
  • Cheapest if commercially insured: Foundayo $25/mo with savings card.
  • Cheapest if uninsured: compounded telehealth $150-$400/mo OR Wegovy NovoCare at $199/mo for a new patient's first two months, then $349/mo.
  • You need a real prescriber, real BMI documentation, and a willingness to push back on insurance denials.
  • Don't buy “research peptides” from unlicensed gray-market sellers — they are not legal pharmacies and have caused real patient harm.

Related research and tools

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 1 Indications and Usage (adults with obesity, or overweight with a weight-related comorbidity). DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 1 Indications and Usage. DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Novo Nordisk Inc. NovoCare Pharmacy direct-pay program for Wegovy — patient-facing pricing tiers updated 2026. Novo Nordisk patient program. 2026. https://www.novocare.com/patient/medicines/wegovy.html
  4. 4.Eli Lilly and Company. LillyDirect Self Pay Pharmacy Solutions for Zepbound — pricing tiers December 2025 update. Eli Lilly patient program. 2026. https://lillydirect.lilly.com/pharmacy-solutions/zepbound
  5. 5.Eli Lilly and Company. FOUNDAYO (orforglipron) US Prescribing Information and Lilly Savings Card. FDA Approved Labeling + Lilly patient program. 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
  6. 6.US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — Consumer Update. FDA Drug Safety Communication. 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
  7. 7.US Food and Drug Administration. Tirzepatide injection products: Resolution of shortage. FDA Drug Shortages. FDA Drug Shortages Database. 2025. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide+Injection
  8. 8.Pharmacy Compounding Accreditation Board. PCAB Accreditation Standards for Compounded Sterile and Nonsterile Preparations (USP 797 and 503A). PCAB / Accreditation Commission for Health Care. 2025. https://www.achc.org/pcab/

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Frequently Asked Questions

Yes. Wegovy, Zepbound, Ozempic, and Mounjaro are all federally controlled prescription drugs in the United States — they cannot be sold over-the-counter or imported without a valid prescription from a licensed clinician. Compounded semaglutide and tirzepatide also require a prescription, dispensed by a licensed compounding pharmacy.
Yes. Telehealth providers like Sequence, Found, Hims, Ro, Calibrate, and others can prescribe GLP-1 medications after a virtual evaluation that typically includes a medical history form, height/weight, and sometimes a video visit. Most reputable telehealth providers require a recent A1C, BMI documentation, or lab work before prescribing.
FDA-approved indications: Wegovy and Zepbound for adults with obesity, or overweight with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, etc.). The labels don't state BMI numbers; in practice that means BMI ≥30, or BMI ≥27 with a comorbidity — the cutoffs the pivotal trials enrolled. Ozempic and Mounjaro are FDA-approved only for people with type 2 diabetes (including cardiovascular risk-reduction indications within type 2 diabetes). Telehealth and compounded vendors sometimes prescribe outside FDA criteria; that's a clinical judgment call between you and the prescriber.
Brand-name list prices run about $1,000-$1,350/mo, but the makers now sell direct to self-pay patients: Wegovy through NovoCare for $349/mo ($199 for a new patient's first two months), Zepbound through LillyDirect for $299-$449/mo by dose, Ozempic for $349/mo ($499 at 2 mg) and Mounjaro from $499/mo. Compounded semaglutide via 503A telehealth pharmacies ranges $150-$400/mo depending on dose and provider. See our pricing index for current numbers.
Telehealth is faster than in-person primary care for most patients: a same-day or next-day async visit, electronic prescription to a contracted pharmacy, and shipment within 3-7 days. In-person paths via PCP or weight-management clinic typically take 2-6 weeks because of scheduling, prior authorization, and pharmacy stocking delays.

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

Pricing Compare

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

Pricing Compare

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

Pricing Compare

Get started →